[非小细胞肺癌中EGFR和ROS-1基因突变 共存1例报道]。

Q4 Medicine

中国肺癌杂志 Pub Date : 2025-06-20 DOI:10.3779/j.issn.1009-3419.2025.102.26

Juan Zhao, Jiaofeng Yu, Ye Fu, Yan Zhao, Mingli Zhao

{"title":"[非小细胞肺癌中EGFR和ROS-1基因突变\u2029共存1例报道]。","authors":"Juan Zhao, Jiaofeng Yu, Ye Fu, Yan Zhao, Mingli Zhao","doi":"10.3779/j.issn.1009-3419.2025.102.26","DOIUrl":null,"url":null,"abstract":"Lung cancer represents one of the most prevalent malignant tumors globally, and its treatment has entered the era of targeted therapy. The epidermal growth factor receptor (EGFR) mutation is a common type of genetic mutation in non-small cell lung cancer (NSCLC), while c-ros oncogene 1 receptor tyrosine kinase (ROS-1) fusion mutation is a rare mutation site. Currently, there are few case reports on the coexistence of EGFR and ROS-1 gene mutations. This study reports a case of NSCLC with coexisting EGFR and ROS-1 gene mutations, aiming to provide relevant treatment strategies for clinical practice.\u2029.","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 6","pages":"482-486"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257172/pdf/","citationCount":"0","resultStr":"{\"title\":\"[A Case Report of Coexistence of EGFR and ROS-1 Gene Mutations \\u2029in Non-small Cell Lung Cancer].\",\"authors\":\"Juan Zhao, Jiaofeng Yu, Ye Fu, Yan Zhao, Mingli Zhao\",\"doi\":\"10.3779/j.issn.1009-3419.2025.102.26\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lung cancer represents one of the most prevalent malignant tumors globally, and its treatment has entered the era of targeted therapy. The epidermal growth factor receptor (EGFR) mutation is a common type of genetic mutation in non-small cell lung cancer (NSCLC), while c-ros oncogene 1 receptor tyrosine kinase (ROS-1) fusion mutation is a rare mutation site. Currently, there are few case reports on the coexistence of EGFR and ROS-1 gene mutations. This study reports a case of NSCLC with coexisting EGFR and ROS-1 gene mutations, aiming to provide relevant treatment strategies for clinical practice.\\u2029.\",\"PeriodicalId\":39317,\"journal\":{\"name\":\"中国肺癌杂志\",\"volume\":\"28 6\",\"pages\":\"482-486\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257172/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国肺癌杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3779/j.issn.1009-3419.2025.102.26\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国肺癌杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3779/j.issn.1009-3419.2025.102.26","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

肺癌是全球最常见的恶性肿瘤之一，其治疗已进入靶向治疗时代。表皮生长因子受体（EGFR）突变是非小细胞肺癌（NSCLC）中一种常见的基因突变类型，而c-ros癌基因1受体酪氨酸激酶（ROS-1）融合突变是一种罕见的突变位点。目前，EGFR与ROS-1基因突变共存的病例报道较少。本研究报告1例EGFR和ROS-1基因突变共存的NSCLC，旨在为临床提供相关的治疗策略。 。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[A Case Report of Coexistence of EGFR and ROS-1 Gene Mutations  in Non-small Cell Lung Cancer].

Lung cancer represents one of the most prevalent malignant tumors globally, and its treatment has entered the era of targeted therapy. The epidermal growth factor receptor (EGFR) mutation is a common type of genetic mutation in non-small cell lung cancer (NSCLC), while c-ros oncogene 1 receptor tyrosine kinase (ROS-1) fusion mutation is a rare mutation site. Currently, there are few case reports on the coexistence of EGFR and ROS-1 gene mutations. This study reports a case of NSCLC with coexisting EGFR and ROS-1 gene mutations, aiming to provide relevant treatment strategies for clinical practice. .

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中国肺癌杂志 Medicine-Pulmonary and Respiratory Medicine

CiteScore

1.40

自引率

0.00%

发文量

5131

审稿时长

14 weeks

期刊介绍： Chinese Journal of Lung Cancer(CJLC, pISSN 1009-3419, eISSN 1999-6187), a monthly Open Access journal, is hosted by Chinese Anti-Cancer Association, Chinese Antituberculosis Association, Tianjin Medical University General Hospital. CJLC was indexed in DOAJ, EMBASE/SCOPUS, Chemical Abstract(CA), CSA-Biological Science, HINARI, EBSCO-CINAHL,CABI Abstract, Global Health, CNKI, etc. Editor-in-Chief: Professor Qinghua ZHOU.

[非小细胞肺癌中EGFR和ROS-1基因突变 共存1例报道]。

摘要

[非小细胞肺癌中EGFR和ROS-1基因突变 共存1例报道]。